TD Cowen sets USD 9.00 target for Maravai LifeSciences stock

Published on 10/15/2026 at 20:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 51.44 million on August 6, 2026. Maravai LifeSciences stock costs EUR 6.10 on October 15, 2026 at 8:33 p.m. CEST, while Nasdaq MRVI is up 4.73 percent versus USD 6.55.

Analyst coverage and results

TD Cowen initiated coverage with a USD 9.00 target on October 5, 2026.
Second-quarter revenue reached USD 51.44 million against USD 48.67 million consensus.
Maravai LifeSciences stock costs EUR 6.10 at Lang & Schwarz on October 15, 2026 at 8:33 p.m. CEST, 4.73 percent above the Nasdaq prior close of USD 6.55.
Maravai LifeSciences will hold its third-quarter earnings call on November 4, 2026.

MRVI, US56600D1072, Illustration mit AI erstellt.

TD Cowen initiated coverage of Maravai LifeSciences with a Buy rating and a USD 9.00 price target on October 5, 2026, according to MarketBeat. Against the Nasdaq price of USD 6.86 on October 15, 2026, the target stood 31.20 percent higher. At Lang & Schwarz, MRVI was trading at EUR 6.10 on October 15, 2026 at 8:33 p.m. CEST; on Nasdaq, the stock was up 4.73 percent versus its USD 6.55 prior close.

Revenue beat the estimate

Maravai reported second-quarter 2026 revenue of USD 51.44 million for the period ended June 30, 2026, compared with USD 48.67 million expected by analysts, a 5.69 percent beat. The figures were reported in the company results covered by MarketBeat. Net income was negative USD 21.63 million in the same quarter, while operating loss was USD 15.09 million.

Stock sits within its yearly range

MarketBeat listed Maravai's 52-week range at USD 2.55 to USD 9.42 on October 6, 2026. The Nasdaq price of USD 6.86 on October 15, 2026 was 27.07 percent below that high and 168.98 percent above the low. Trading volume reached 975,239 shares against an average of 3,232,526 shares in the latest finance quote.

Valuation and next date

Maravai had a market capitalization of USD 1.9 billion and a negative price-to-earnings ratio of 12.80 as of October 15, 2026. The company reported 415 full-time employees and operates in biotechnology, supplying nucleic-acid products, enzymes and biologics safety-testing products. Its investor-relations calendar lists the third-quarter 2026 earnings conference call for November 4, 2026 at 5:00 p.m. ET, as shown on Maravai LifeSciences.

Comparison with peers

MRVI (Nasdaq, USD): plus 4.73 percent, P/E minus 12.80, market capitalization USD 1.9 billion
Moderna (Nasdaq, USD): plus 5.02 percent, P/E minus 29.81, market capitalization USD 94.9 billion
BioNTech (Nasdaq, USD): plus 1.76 percent, P/E minus 11.79, market capitalization USD 22.6 billion

Trading levels for investors

Maravai's Nasdaq move placed it between the two peer moves in this comparison, while the company's market value remained far below Moderna's and BioNTech's. The combination of a USD 9.00 TD Cowen target, second-quarter revenue above consensus and a November 4 earnings date gives the stock three concrete reference points beyond its intraday euro quote.

Maravai LifeSciences was trading at EUR 6.10 at Lang & Schwarz on October 15, 2026 at 8:33 p.m. CEST. On Nasdaq, MRVI was up 4.73 percent against the USD 6.55 prior close on October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Maravai LifeSciences stock.